Beta Bionics, Inc. (BBNX)
Nasdaq: BBNX · Surgical & Medical Instruments & Apparatus · Irvine, CA · filing with the SEC since 2016
Who owns Beta Bionics, Inc.
As filed with the SECHolders of 5% or more
11
T. Rowe Price Associates, Inc. holds 16.6% of COMMON STOCK, as its SCHEDULE 13G filed Oct 7, 2026 says.
Directors and officers
11
report now, of 11 people on the record since 2025. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 11 named at left.
Holders of 5% or moreshare of the class, as filed
T. Rowe Price Associates, Inc.
SCHEDULE 13G · filed Oct 7, 2026 · COMMON STOCK
Eventide Asset Management, LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.0001 par value per share · 11.3% in Feb 5, 2025
Dapice Joshua J.
SCHEDULE 13G/A · filed Nov 12, 2025 · Common Stock, $0.0001 par value per share (the "Shares") · 7.9% in Feb 7, 2025
Levy Guy
SCHEDULE 13G/A · filed May 8, 2026 · Common Stock
Morgan Stanley
SCHEDULE 13G/A · filed Nov 7, 2025 · Common Stock · 6.8% in Aug 7, 2025
Sands Capital Life Sciences Pulse Fund II. L.P.
SCHEDULE 13G/A · filed Aug 13, 2025 · Common Stock · 7.3% in Apr 9, 2025
Dapice Joshua J.
SCHEDULE 13G/A · filed May 12, 2026 · Common Stock, $0.0001 par value per share (the "Shares") · 9.9% in Feb 9, 2026
Divisadero Street Capital Management, LP
SCHEDULE 13G · filed Jul 24, 2026 · Common Stock, $0.0001 par value per share
Blackrock, Inc.
SCHEDULE 13G · filed Oct 17, 2025 · Common Stock
Guy Levy
SCHEDULE 13G/A · filed Feb 12, 2026 · Common Stock · 8.8% in May 2, 2025
Point72 Asset Management, L.P.
SCHEDULE 13G · filed Feb 23, 2026 · Common Stock, par value $0.0001 per share
RTW Investments, LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.0001 par value · reported falling below 5%, from 5.7% in Feb 17, 2026
Perceptive Advisors LLC
SCHEDULE 13G/A · filed Aug 7, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 5.1% in May 15, 2025
Millennium Management LLC
SCHEDULE 13G/A · filed Oct 16, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.3% in Sep 19, 2025
Farallon Capital Management, L.L.C.
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock, $0.0001 par value per share (the "Shares") · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 5.09% in Oct 30, 2025
Wellington Hadley Harbor Aggregator IV, L.P.
SCHEDULE 13G/A · filed Feb 10, 2026 · Common Stock · reported falling below 5%, from 9% in May 12, 2025
Wellington Management Group LLP
SCHEDULE 13G/A · filed Feb 10, 2026 · Common Stock · reported falling below 5%, from 9% in May 12, 2025
What BBNX reports owning in othersstakes of 5% or more, and other ties
Beta Bionics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
55sales
0purchases
34sales on a scheduled plan
8people selling
$5.4Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 12 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Hopman Mark | Chief Commercial Officer | 16 | $2.3M | 11 | 0 | $0 |
| Feider Stephen | Chief Financial Officer | 11 | $1.2M | 7 | 0 | $0 |
| Saint Sean | President & CEO | 5 | $800,000 | 1 | 0 | $0 |
| Mensinger Mike | Chief Product Officer | 9 | $600,000 | 5 | 0 | $0 |
| Russell Steven Jon | Chief Medical Officer | 4 | $200,000 | 0 | 0 | $0 |
| Jones Christy | director | 4 | $200,000 | 4 | 0 | $0 |
| Lezack Adam | director | 4 | $100,000 | 4 | 0 | $0 |
| Palasis Maria | director | 2 | $0 | 2 | 0 | $0 |